These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 1682541)

  • 41. Emergency vaccination against epidemic meningitis in Ghana: implications for the control of meningococcal disease in West Africa.
    Woods CW; Armstrong G; Sackey SO; Tetteh C; Bugri S; Perkins BA; Rosenstein NE
    Lancet; 2000 Jan; 355(9197):30-3. PubMed ID: 10615888
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A native outer membrane vesicle vaccine confers protection against meningococcal colonization in human CEACAM1 transgenic mice.
    Pajon R; Buckwalter CM; Johswich KO; Gray-Owen SD; Granoff DM
    Vaccine; 2015 Mar; 33(11):1317-1323. PubMed ID: 25662856
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Current status of meningococcal group B vaccine candidates: capsular or noncapsular?
    Diaz Romero J; Outschoorn IM
    Clin Microbiol Rev; 1994 Oct; 7(4):559-75. PubMed ID: 7834605
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effectiveness of a mass immunization campaign against serogroup C meningococci in children in the federal state of Santa Catarina, Brazil.
    Kupek E; Puricelli RC; Westrupp MH
    Braz J Infect Dis; 2001 Dec; 5(6):324-31. PubMed ID: 11980595
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety of group C meningococcal vaccine.
    Commun Dis Rep CDR Wkly; 2000 Sep; 10(35):311, 314. PubMed ID: 10992627
    [No Abstract]   [Full Text] [Related]  

  • 46. Meningococcal carriage, meningococcal disease and vaccination.
    Hassan-King MK; Wall RA; Greenwood BM
    J Infect; 1988 Jan; 16(1):55-9. PubMed ID: 3130424
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Acceptability of meningococcal serogroup B vaccine among parents and health care workers in Italy: a survey.
    Mameli C; Faccini M; Mazzali C; Picca M; Colella G; Duca PG; Zuccotti GV
    Hum Vaccin Immunother; 2014; 10(10):3004-10. PubMed ID: 25483638
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Outbreak of group C meningococcal disease in Australian Aboriginal children.
    Booy R
    Lancet; 1995 Aug; 346(8974):572-3. PubMed ID: 7658793
    [No Abstract]   [Full Text] [Related]  

  • 49. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age.
    Peltola H; Mäkelä H; Käyhty H; Jousimies H; Herva E; Hällström K; Sivonen A; Renkonen OV; Pettay O; Karanko V; Ahvonen P; Sarna S
    N Engl J Med; 1977 Sep; 297(13):686-91. PubMed ID: 408682
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effectiveness of Meningococcal B Vaccine against Endemic Hypervirulent Neisseria meningitidis W Strain, England.
    Ladhani SN; Giuliani MM; Biolchi A; Pizza M; Beebeejaun K; Lucidarme J; Findlow J; Ramsay ME; Borrow R
    Emerg Infect Dis; 2016 Feb; 22(2):309-11. PubMed ID: 26811872
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Control of epidemic meningococcal meningitis by mass vaccination. II. Persistence of antibody four years after vaccination.
    Mohammed I; Onyemelukwe GC; Obineche EN; Gupta N; Oyeyinka GO
    J Infect; 1984 Sep; 9(2):197-202. PubMed ID: 6438245
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Meningococcal C conjugate vaccine effectiveness before and during an outbreak of invasive meningococcal disease due to Neisseria meningitidis serogroup C/cc11, Tuscany, Italy.
    Pezzotti P; Miglietta A; Neri A; Fazio C; Vacca P; Voller F; Rezza G; Stefanelli P
    Vaccine; 2018 Jul; 36(29):4222-4227. PubMed ID: 29895504
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Design of clinical trials with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway.
    Bjune G; Closs O; Frøholm LO; Grønnesby JK; Høiby EA; Nøkleby H
    NIPH Ann; 1991 Dec; 14(2):81-91; discussion 91-3. PubMed ID: 1812439
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Meningococcal disease: the advances and challenges of meningococcal disease prevention.
    Yogev R; Tan T
    Hum Vaccin; 2011 Aug; 7(8):828-37. PubMed ID: 21832882
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prolonged outbreak of B meningococcal disease in the Seine-Maritime department, France, January 2003 to June 2005.
    Rouaud P; Perrocheau A; Taha MK; Sesboué C; Forgues AM; Parent du Châtelet I; Levy-Bruhl D
    Euro Surveill; 2006 Jul; 11(7):178-81. PubMed ID: 16966800
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mucosal immunity and optimizing protection with meningococcal serogroup B vaccines.
    Heyderman RS; Davenport V; Williams NA
    Trends Microbiol; 2006 Mar; 14(3):120-4. PubMed ID: 16469496
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy.
    Findlow J; Borrow R; Snape MD; Dawson T; Holland A; John TM; Evans A; Telford KL; Ypma E; Toneatto D; Oster P; Miller E; Pollard AJ
    Clin Infect Dis; 2010 Nov; 51(10):1127-37. PubMed ID: 20954968
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety of meningococcal polysaccharide vaccine serogroup "A" (Pilot Study).
    Bahl MR
    Med J Zambia; 1975 Dec-1976 Jan; 9(6):166. PubMed ID: 818845
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Clinical trials of the new Norwegian vaccine against diseases caused by Meningococcus B].
    Bjune G; Nøkleby H; Hareide B
    Tidsskr Nor Laegeforen; 1990 Feb; 110(5):614-7. PubMed ID: 2408194
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Bacterial meningitis caused by Neisseria meningitidis. Prophylactic measures].
    Magdzik W
    Przegl Epidemiol; 2004; 58(2):241-51. PubMed ID: 15521103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.